|Table of Contents|

Clinical characteristics and prognostic analysis of primary central nervous system lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1112-1117
Research Field:
Publishing date:

Info

Title:
Clinical characteristics and prognostic analysis of primary central nervous system lymphoma
Author(s):
MI Qian1; BAI Sijun1; 2; GENG Ye1; 2; GAO Yinan1; 2; ZHANG Caixia1; 2; HE Jianxia1; 2
1.The Fifth Clinical Medical College of Shanxi Medical University,Shanxi Taiyuan 030012，China；2.Hematology Department,Shanxi Provincial People's Hospital，Shanxi Taiyuan 030012，China.
Keywords:
central nervous system; diffuse large B cell lymphoma; MYD88; PIM1; prognosis
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.06.025
Abstract:
Objective：To explore the clinicopathological and molecular features and prognostic factors in patients with primary central nervous system lymphoma (PCNSL).Methods：Collect clinical data and tissues amples of 35 patients with PCNSL in Shanxi Provincial People's Hospital from March 2013 to May 2021,summarize the clinicopathological characteristics and apply second-generation sequencing technology to detect lymphoma-related genes.The effects of age,lesion location,lactate dehydrogenase (LDH) and immunohistochemistry on prognosis were analyzed，and the differences in overall survival (OS) in different gene mutation groups and treatment regimens were compared.Results：The most universal gene mutation was MYD88 (66.7%,12/18)，IGLL5,PIM1(38.9%,7/18).The OS of PIM1 mutation group and IGLL5 mutation group was significantly lower than that of the non-mutation group (P=0.019 and 0.021).Multivariate Cox regression analysis showed that LDH and different treatment regimens were independent prognostic factors of PCNSL patients (P=0.007 and 0.002).The OS of the group receiving high-dose methotrexate (MTX) and rituximab (R) was significantly better than the untreated group (P=0.005 and ＜0.001).There was a trend of survival benefit in the group using broughton tyrosine kinase inhibitor (BTKi) compared with the group not receiving it,but there was no statistical difference.Conclusion：Elevated serum LDH was significantly associated with poor prognosis.The patients with PIM1 and IGLL5 mutations had inferior survival.The treatment with MTX and R can improve the survival of patients.

References:

［1］ DEWITT JC，MOCK A，LOUIS DN.The 2016 WHO classification of central nervous system tumors：what neurologists need to know［J］.Curr Opin Neurol，2017，30（6）： 643-649.
[2] 朱军.我如何治疗原发中枢神经系统淋巴瘤［J］.中华血液学杂志，2018，39（5）：372-375. ZHU J.How I treat the primary central nervous system lymphoma［J］.Chin J Hematol， 2018，39（5）：372-375.
[3] CHIHARA D，FOWLER NH，OKI Y，et al.Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma：a SEER database analysis［J］.Oncotarget，2018，9（48）：28897-28902.
[4] CAMPO E，SWERDLOW SH，HARRIS NL，et al.The 2008 WHO classification of lymphoid neoplasms and beyond：evolving concepts and practical applications［J］.Blood，2011，117（19）：5019-5032.
[5] 黄浦，陈舒，杨鑫，等.p53及BCL2蛋白在双表达弥漫大B细胞淋巴瘤中的预后判断价值［J］.中华血液学杂志，2019，40（7）：589-593. HUANG P，CHEN S，YANG X，et al.Prognostic evaluation of p53 and BCL2 proteins in MYC/BCL2 double expression DLBCL［J］.Chin J Hematol，2019，40（7）：589-593.
[6] YUAN XG，HUANG YR，YU T，et al.Primary central nervous system lymphoma in China：a single-center retrospective analysis of 167 cases［J］.Ann Hematol，2020，99 （1）：93-104.
[7] MENDEZ JS，OSTROM QT，GITTLEMAN H，et al.The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades［J］.Neuro-Oncology，2018，20（5）：687-694.
[8] PATEL B，CHACKO G，NAIR S，et al.Clinicopathological correlates of primary central nervous system lymphoma：experience from a tertiary care center in South India［J］. Neurol India，2015，63（1）：77-82.
[9] CHEN RR，ZHOU D，WANG LL，et al.MYD88L265P and CD79B double mutations type （MCD type）of diffuse large B-cell lymphoma：mechanism，clinical characteristics，and targeted therapy［J］.Ther Adv Hematol，2022，13：20406207211072839.
[10] PHELAN JD，YOUNG RM，WEBSTER DE，et al.A multiprotein supercomplex controlling oncogenic signalling in lymphoma［J］.Nature，2018，560（7718）：387-391.
[11] CALIMERI T，STEFFANONI S，FOPPOLI M，et al.Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma［J］. Expert Opin Ther Targets，2021，25（9）：749-760.
[12] BONZHEIM I，SANDER P，VILLALOBOS JS，et al.The molecular hallmarks of primary and secondary vitreoretinal lymphoma［J］.Blood Adv，2022，6（5）：1598-1607.
[13] ZHOU Y，LIU W，XU Z，et al.Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes［J］.Neoplasia，2018，2 0（10）：1059-1069.
[14] FOULKS JM，CARPENTER KJ，LUO B，et al.A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas［J］.Neoplasia，2014，16（5）：4 03-412.
[15] D'AGOSTINO M，ZACCARIA GM，ZICCHEDDU B，et al.Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing［J］.Clin Cancer Res，2020，26（18）：4832-4841.
[16] GAO F，TIAN L，SHI H，et al.Geneticl and scape of relapsed and refractory diffuse large B-cell lymphoma：a systemic review and association analysis with next-generation sequencing［J］.Front Genet，2021，12：677650.
[17] FERRERI AJM，CWYNARSKI K，PULCZYNSKI E，et al.Chemoimmunotherapy with methotrexate，cytarabine，thiotepa，andrituximab （MATRix regimen） in patients with primary CNS lymphoma：results of the first randomisation of the international extranodal lymphoma study group-32（IELSG32） phase 2 trial［J］.Lancet Haematol， 2016， 3（5）：e217-e227.
[18] BROMBERG JEC，ISSA S，BUKANINA K，et al.Rituximab in patients with primary CNS lymphoma（HOVON 105/ALLG NHL 24）：a randomized，open-lable，phase 3 intergroup study［J］.Lancet Oncol，2021，20（2）：216-228.
[19] 庞迪文，陈菲莉，郭汉国，等.大剂量甲氨蝶呤和替莫唑胺与利妥昔单抗联合治疗原发性中枢神经系统淋巴瘤患者的临床疗效［J］.中国实验血液学杂志，2021，29（4）：1175-1 180. PANG DW，CHEN FL，GUO HG，et al.Clinical efficacy of high dose methotrexate，temozolomide and rituximab in the treatment of patients with primary central nervous system lymphoma［J］.J Exp Hematol，2021，29（4）：1175-1180.
[20] GHESQUIERES H，CHEVRIER M，LAADHARI M，et al.Lenalidomide in combination with intravenous rituximab （REVRI）in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma：a multicenter prospective 'proof of concept' phase II study of the French oculo-cerebral lymphoma （LOC）network and the lymphoma study association （LYSA）［J］.Ann Oncol，2019，30（4）：621-628.
[21] GLASS J，WON M，SCHULTZ CJ，et al.Phase I and II study of induction chemotherapy with methotrexate，rituximab，and temozolomide，followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma：NR Goncology RTOG0227［J］.J Clin Oncol，2016，34（14）：1620-1625.
[22] SHAO L，XU CS，WU HJ，et al.Recent progress on primary central nervous system lymphoma-from bench to bedside［J］.Front Oncol，2021，11：689843.
[23] LEWIS KL，CHIN CK，MANOS K，et al.Ibrutinib for central nervous system lymphoma：the Australasian lymphoma Alliance/MD anderson cancer center experience［J］. Br J Haematol，2020，192（6）：1049-1053.
[24] CHONG EA，RUELLA M，SCHUSTER SJ，et al.Five-year out comes for refractory B-cell lymphomas with CAR T-cell therapy［J］.N Engl J Med，2021，384（7）：673-674.
[25] SIDDIQI T，WANG XL，BLANCHARD MS，et al.CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma［J］.Blood Adv，2021，5（20）：4059-406 3.
[26] FRIGAULT MJ，DIETRICH J，GALLAGHER KME，et al.Safety and efficacy of tisagenlecleucel in primary CNS lymphoma：a phase I/II clinical trial［J］.Blood，2022，13 9（15）：2306-2315.
[27] FERRERI AJM，BLAY JY，RENI M，et al.Prognostics coring system for primary CNS lymphomas：the international extranodal lymphoma study group experience［J］.J Clin Oncol，2003，21（2）：266-272.
[28] ABREY LE，BEN-PORAT L，PANAGEAS KS，et al.Primary central nervous system lymphoma：the memorial sloan-kettering cancer center prognostic model［J］.J Clin Oncol， 2006，24（20）：5711-5715.
[29] 刘诤，张鹏帅，宋子木，等.原发性中枢神经系统淋巴瘤的临床特征及影响预后的相关因素［J］.临床神经外科杂志，2021，18（4）：419-423. LIU Z，ZHANG PS，SONG ZM，et al.Clinical characteristics and prognostic factors of primary central nervous system lymphoma［J］.J Clin Neurosurg，2021，18（4）：419-423.
[30] 王进隆，张旭东，陈清江，等.原发中枢神经系统淋巴瘤患者的临床特点和预后分析［J］.医学研究生学报，2020，33（11）：1171-1175. WANG JL，ZHANG XD，CHEN QJ，et al.Clinical features and prognosis of primary central nervous system lymphoma［J］.J Med Postgra，2020，33（11）：1171-1175.

Memo

Memo:
山西省自然科学基金（编号：201901D111435）
Last Update: 1900-01-01